Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in SynapCell’s Genetic Absence Epilepsy Model (GAERS)
Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first-in-class T-type calcium channel modulator CX-8998 significantly suppressed seizures in two translational animal models of absence epilepsy. CX-8998 was more effective than the commonly prescribed anti-epileptic drug ethosuximide in reducing absence seizures in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a highly predictive model of absence epilepsy. In the GAERS rats, CX-8998 showed near complete suppression of seizure activity (99% reduction in both number and cumulative duration of spike wave discharges) at 10 mg/kg, a well-tolerated dose that results in human-achievable drug concentrations. In contrast, ethosuximide suppressed 60% of seizure activity at exposures associated with the optimal human dose. The poster being presented today in the Anticonvulsant and Antiepileptic Therapies Session (289.21) of the Society for Neuroscience Annual Meeting held in San Diego, CA, also described CX-8998’s preclinical efficacy against seizure as tested previously in the WAG/Rij rat model.
Cavion has presented the data at the Society for Neuroscience Annual Meeting demonstrating that its T-type calcium channel modulator CX-8998 significantly suppressed seizures in GAERS and WAG/Rij animal models of absence epilepsy.